Oxytrol Patch
Product Images NDC 0023-6153

10 FDA label images from Allergan, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Oxytrol (NDC 0023-6153). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Allergan, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

The Structural Formula For Oxybutynin Is An Antispasmodic, Anticholinergic Agent. Oxybutynin Is Administered As A Racemate Of R- And S-isomers. Chemically, Oxybutynin Is D, L (racemic) 4-diethylamino-2-butynyl Phenylcyclohexylglycolate. The Empirical Formula Of Oxybutynin Is C22h31no3. (Oxytrol 01)

The Structural Formula For Oxybutynin Is An Antispasmodic, Anticholinergic Agent. Oxybutynin Is Administered As A Racemate Of R- And S-isomers. Chemically, Oxybutynin Is D, L (racemic) 4-diethylamino-2-butynyl Phenylcyclohexylglycolate. The Empirical Formula Of Oxybutynin Is C22h31no3. (Oxytrol 01)
Chemical structure of oxybutynin, showing its molecular arrangement with aromatic, ester, hydroxyl, alkyl, and amine groups visible as part of the compound's chemical formula.*
FDA Label Image

Figure 1: Side And Top Views Of The Oxytrol System.(not To Scale) (Oxytrol 02)

Figure 1: Side And Top Views Of The Oxytrol System.(not To Scale) (Oxytrol 02)
An illustration diagram of the OXYTROL transdermal patch showing a side view and a top view with dimensions. The side view labels three layers: PET/EVA backing film, adhesive/drug layer, and overlapped release liner. The top view shows the patch's rectangular shape with rounded corners measuring 7.6 cm by 5.7 cm.*
FDA Label Image

Figure 2: Average Plasma Oxybutynin Concentrations (cp) In 24 Healthy Male And Female Volunteers During Single-dose Application Of Oxytrol 3.9 mg/day To The Abdomen, Buttock, And Hip (system Removal At 96 Hours). (Oxytrol 03)

Figure 2: Average Plasma Oxybutynin Concentrations (cp) In 24 Healthy Male And Female Volunteers During Single-dose Application Of Oxytrol 3.9 mg/day To The Abdomen, Buttock, And Hip (system Removal At 96 Hours). (Oxytrol 03)
A line graph showing plasma concentration (Cp) in ng/mL over time in hours post-application of the OXYTROL transdermal patch. The graph compares Cp levels following patch application to three different sites: abdomen, buttock, and hip, displaying similar pharmacokinetic profiles with peak concentrations occurring between 24 and 48 hours and a decline after 96 hours.*
FDA Label Image

Figure 3: Average (sem) Steady-state Oxybutynin And N-desethyloxybutynin Plasma Concentrations (cp) Measured In 13 Healthy Volunteers Following The Second Transdermal System Application In A Multiple-dose, Randomized, Crossover Study. (Oxytrol 04)

Figure 3: Average (sem) Steady-state Oxybutynin And N-desethyloxybutynin Plasma Concentrations (cp) Measured In 13 Healthy Volunteers Following The Second Transdermal System Application In A Multiple-dose, Randomized, Crossover Study. (Oxytrol 04)
A pharmacokinetic graph showing plasma concentration (Cp in ng/mL) of N-desethyloxybutynin and oxybutynin over time (hours post 2nd system application) up to 96 hours. Concentrations of both compounds rise, peak around 24–48 hours, and then decline. N-desethyloxybutynin shows higher plasma levels compared to oxybutynin throughout the period.*
FDA Label Image

Figure 4: Average Plasma Concentrations (cp) Measured After A Single, 96-hour Application Of The Oxytrol 3.9 mg/day System (aucinf/96) And A Single, 5 mg, Oral Immediate-release Dose Of Oxybutynin Chloride (aucinf/8) In 16 Healthy Male And Female Volunteers. (Oxytrol 05)

Figure 4: Average Plasma Concentrations (cp) Measured After A Single, 96-hour Application Of The Oxytrol 3.9 mg/day System (aucinf/96) And A Single, 5 mg, Oral Immediate-release Dose Of Oxybutynin Chloride (aucinf/8) In 16 Healthy Male And Female Volunteers. (Oxytrol 05)
Bar chart comparing plasma concentrations (Cp ng/mL) of Oxybutynin and its metabolite N-desethyloxybutynin after administration of OXYTROL 3.9 mg/d transdermal patch versus oral immediate-release formulation. OXYTROL shows higher oxybutynin and lower metabolite level, while oral immediate-release shows higher metabolite concentration.*
FDA Label Image

· Do Not Use The Same Area For The Patch For At Least 1 Week. You May Choose To Try Different Sites When Using Oxytrol To Find The Sites That Are Most Comfortable For You And Where Clothing Will Not Rub Against It. (Oxytrol 06)

· Do Not Use The Same Area For The Patch For At Least 1 Week. You May Choose To Try Different Sites When Using Oxytrol To Find The Sites That Are Most Comfortable For You And Where Clothing Will Not Rub Against It. (Oxytrol 06)
An instructional anatomical illustration showing the recommended application sites for OXYTROL (oxybutynin) transdermal patch on the human body. The diagram depicts front, side, and back views of a male figure, highlighting the abdomen, hips, and buttocks as appropriate placement areas for the patch.*
FDA Label Image

· Each Patch Is Sealed In Its Own Protective Pouch. See Figure B.· When You Are Ready To Put On Your Oxytrol Patch, Tear Open The Pouch And Remove The Patch. See Figure C. (Oxytrol 07)

· Each Patch Is Sealed In Its Own Protective Pouch. See Figure B.· When You Are Ready To Put On Your Oxytrol Patch, Tear Open The Pouch And Remove The Patch. See Figure C. (Oxytrol 07)
Illustration showing two figures related to the OXYTROL transdermal patch: Figure B depicts the patch with directional arrows indicating orientation, while Figure C shows hands peeling the patch's protective backing, demonstrating its application process.*
FDA Label Image

· The Sticky Adhesive Side Of The Patch Is Covered By 2 Strips Of Overlapping Protective Liner. See Figure D.· Remove The First Piece Of The Protective Liner And Place The Patch, Adhesive Face Down, Firmly Onto The Skin. See Figure E. (Oxytrol 08)

· The Sticky Adhesive Side Of The Patch Is Covered By 2 Strips Of Overlapping Protective Liner. See Figure D.· Remove The First Piece Of The Protective Liner And Place The Patch, Adhesive Face Down, Firmly Onto The Skin. See Figure E. (Oxytrol 08)
Instructional illustration showing two steps of applying the OXYTROL transdermal patch. The first image depicts hands peeling the protective liner from the patch, marked with 'PULL HERE.' The second image shows the patch being smoothed onto the lower abdominal skin of a person using fingers.*
FDA Label Image

· Bend The Patch In Half And Gently Roll The Remaining Part Onto Your Skin Using The Tips Of Your Fingers. As You Roll The Patch In Place, The Second Piece Of The Protective Liner Should Come Off The Patch. See Figure F.· Apply Firm Pressure Over The Surface Of The Patch With Your Fingers To Make Sure The Patch Stays On. See Figure G. (Oxytrol 09)

· Bend The Patch In Half And Gently Roll The Remaining Part Onto Your Skin Using The Tips Of Your Fingers. As You Roll The Patch In Place, The Second Piece Of The Protective Liner Should Come Off The Patch. See Figure F.· Apply Firm Pressure Over The Surface Of The Patch With Your Fingers To Make Sure The Patch Stays On. See Figure G. (Oxytrol 09)
Instructional illustration showing application of the OXYTROL transdermal patch. Figure F depicts a person peeling the liner off the patch before application. Figure G shows the person pressing the patch onto the lower abdominal skin after liner removal, demonstrating proper adhesion technique.*
FDA Label Image

Principal Display Paneloxytrol® (oxybutynin Transdermal System)ndc 0023-6153-083.9 mg/daycontains 8 Transdermal Systems (Oxytrol 0a)

Principal Display Paneloxytrol® (oxybutynin Transdermal System)ndc 0023-6153-083.9 mg/daycontains 8 Transdermal Systems (Oxytrol 0a)
The packaging label for OXYTROL 3.9 mg/day transdermal patch by Allergan, Inc. The label features the proprietary name OXYTROL with the description Oxybutynin Transdermal System prominently displayed. It indicates the strength as 3.9 mg/day and states the package contains 8 transdermal systems. The label includes dosage information and the prescription only designation, along with the NDC 0023-6153-08.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.